IMMUNOGENESIS
ImmunoGenesis develops science-driven immune therapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms.
IMMUNOGENESIS
Industry:
Biotechnology Health Care Health Diagnostics Life Science Medical Therapeutics
Founded:
2019-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.immunogenesis.com
Total Employee:
11+
Status:
Active
Contact:
346-772-0336
Email Addresses:
[email protected]
Total Funding:
23.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Current Employees Featured
Founder
Investors List
Texas HALO Fund
Texas HALO Fund investment in Venture Round - ImmunoGenesis
Juno Capital
Juno Capital investment in Seed Round - ImmunoGenesis
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Grant - ImmunoGenesis
Official Site Inspections
http://www.immunogenesis.com
- Host name: server.group-31.com
- IP address: 190.92.154.54
- Location: Argentina
- Latitude: -34.6022
- Longitude: -58.3845
- Timezone: America/Argentina/Buenos_Aires
More informations about "ImmunoGenesis"
Who We Are – ImmunoGenesis
ImmunoGenesis is an immuno-oncology biopharmaceutical company re-envisioning “cold” tumor treatment. Our deliberate drug development strategy is based in the pathology of cold tumors. …See details»
ImmunoGenesis - Crunchbase Company Profile
ImmunoGenesis closed its last funding round on Jun 27, 2023 from a Venture - Series Unknown round. Who are ImmunoGenesis 's competitors? Alternatives and possible competitors to ImmunoGenesis may include Semma …See details»
Team – ImmunoGenesis
Before joining ImmunoGenesis, Mr. Barlow was Vice President of Operations and Business Development for Geneos Therapeutics. Mr. Barlow played an integral role in the formation of …See details»
ImmunoGenesis, Inc. - LinkedIn
ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company re-envisioning the treatment of "cold" tumors, particularly of immune-excluded tumors.See details»
ImmunoGenesis Company Profile 2024: Valuation, Funding
ImmunoGenesis General Information Description. Developer of immuno-oncology therapeutics designed to create unparalleled cold tumor treatments. The company specializes in developing …See details»
ImmunoGenesis - Contacts, Employees, Board Members, Advisors …
ImmunoGenesis has 2 current employee profiles, including CEO & President James A. Barlow. James A. Barlow CEO & President Michael Curran Co-Founder and SAB HeadSee details»
ImmunoGenesis - Funding, Financials, Valuation & Investors
Dec 1, 2021 How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive …See details»
Investors – ImmunoGenesis
At ImmunoGenesis, we aim to turn cold tumors hot to unlock the potential of immunotherapy for more patients. While traditional approaches and new combination treatments for many cancer types continue to disappoint, …See details»
ImmunoGenesis Expands R&D, Clinical and Business Development …
Jul 28, 2021 ImmunoGenesis is a clinical-stage biotechnology company developing science-driven immune therapies specifically designed to treat tumors lacking activated T cells or …See details»
ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting …
Dec 9, 2020 ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021.. Evofosfamide is the only known …See details»
Inmunogenesis - Crunchbase Company Profile & Funding
Organization. Inmunogenesis . Connect to CRM . Save . Summary. People. Technology. Signals & News. ... Immunogenesis was founded in 2015. Lists Featuring This Company. Edit Lists …See details»
Contact Us - ImmunoGenesis
[email protected]: ImmunoGenesis. JLABS @ TMC 2450 Holcombe Blvd Suite J Houston, TX 77021 . ImmunoGenesis. JLABS @ TMC 2450 Holcombe Blvd Suite J Houston, …See details»
ImmunoGenesis: Acquisition Strengthens “Cold” Tumor
Dec 9, 2020 ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021.; Evofosfamide is the only known …See details»
ImmunoGenesis Expands R&D, Clinical and Business ... - Markets …
Jul 28, 2021 ImmunoGenesis is a clinical-stage biotechnology company developing science-driven immune therapies specifically designed to treat tumors lacking activated T cells or …See details»
ImmunoGenesis Announces Publication of Phase 1 Data on its …
Jun 16, 2021 ImmunoGenesis is a clinical-stage biotechnology company developing therapeutics to catalyze effective immune responses in immunologically cold cancers such as …See details»
ImmunoGenes - Crunchbase Company Profile & Funding
Organization. ImmunoGenes . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ImmunoGenes is a …See details»
ImmunoGenesis Expands R&D, Clinical and Business Development …
Jul 28, 2021 Additionally, ImmunoGenesis was awarded a product development grant of $15.5 million by the Cancer Prevention and Research Institute of Texas, which will help advance its …See details»
Immunogenomics: a foundation for intelligent immune design
Nov 19, 2015 The complexity of the immune system is now being interrogated using methodologies that generate extensive multi-dimensional data. Effective collection, integration …See details»
News – ImmunoGenesis
Nov 3, 2022 ImmunoGenesis today announced the first patient has been dosed in the company’s Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of …See details»